Pemetrexed
Pemetrexed is an active ingredient of the class «antimetabolite».
Chemical compound
What it is used for
- Non-small-cell lung carcinoma
- Malignant pleural mesothelioma
- Benign pleural mesothelioma
- Bronchus carcinoma
- Benign mesothelioma
- Neoplasm
- Mesothelioma
- Adenocarcinoma
- Large cell carcinoma
- Malignant mesothelioma
PEMFEXY™ is a folate analog metabolic inhibitor indicated for: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial…
Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
How it works
- Thymidylate synthase inhibitor
- Dihydrofolate reductase inhibitor
- GAR transformylase inhibitor
Class: antimetabolite
Common side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression Renal failure Bullous and exfoliative skin toxicity Interstitial pneumonitis Radiation recall The most common adverse reactions (incidence ≥ 20%) of pemetrexed, when administered as a single agent are…
Who should not take it
PEMFEXY is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed. History of severe hypersensitivity reaction to pemetrexed.
Pregnancy and breastfeeding
Based on findings from animal studies and its mechanism of action, pemetrexed can cause fetal harm when administered to a pregnant woman. There are no available data on pemetrexed use in pregnant women.
Interactions
- Aspirin — gastrointestinal toxicity, bone marrow failure, nephrotoxicity
- Celecoxib — bone marrow failure, nephrotoxicity, gastrointestinal toxicity
- Diclofenac — gastrointestinal toxicity, nephrotoxicity, bone marrow failure
- Ibuprofen — gastrointestinal toxicity, bone marrow failure, nephrotoxicity
- Indometacin — bone marrow failure, nephrotoxicity, gastrointestinal toxicity
- Ketoprofen — gastrointestinal toxicity, bone marrow failure, nephrotoxicity
- Meloxicam — bone marrow failure, gastrointestinal toxicity, nephrotoxicity
- Naproxen — nephrotoxicity, bone marrow failure, gastrointestinal toxicity
- Piroxicam — gastrointestinal toxicity, bone marrow failure, nephrotoxicity
- Mefenamic acid
Brand names
United States
Axtle · Pemetrexed FOR Injection · Pemfexy
European Union
Pemetrexed Accord · Pemetrexed Fresenius Kabi · Pemetrexed Pfizer (previously Pemetrexed Hospira)
Canada
Taro-Pemetrexed
Other trade names
Ciambra · Pemetrexed baxter · Pemetrexed krka · Pemetrexed lilly · Pemetrexed medac · Pemetrexed pfizer (previously known as pemetrexed hospira uk limited) · Pemetrexed sandoz
Approval status
- US Food and Drug Administration
- prescription · since 2004
- European Medicines Agency
- authorised · since 2004
- Health Canada
- prescription · marketed
- First approval anywhere
- 2004
Codes
- ATC
- L01BA04
- RxNorm CUI
- 68446
- ChEMBL
- CHEMBL225072
- PubChem CID
- 135410875
- UNII
- 04Q9AIZ7NO
- Wikidata
- Q415220
Frequently asked questions
What is Pemetrexed used for?
Pemetrexed is used for: Non-small-cell lung carcinoma, Malignant pleural mesothelioma, Benign pleural mesothelioma, Bronchus carcinoma, Benign mesothelioma, Neoplasm, Mesothelioma, and Adenocarcinoma.
What kind of medicine is Pemetrexed?
Pemetrexed is an active ingredient of the class «antimetabolite».
What are the brand names of Pemetrexed?
Brand names of Pemetrexed include Axtle, Pemetrexed FOR Injection, Pemfexy, Pemetrexed Accord, Pemetrexed Fresenius Kabi, Pemetrexed Pfizer (previously Pemetrexed Hospira), Taro-Pemetrexed, and Ciambra.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)